Cambridge, Mass., November 5th, 2015 / BUSINESS WIRE / -- Pronutria Biosciences™ Inc., a biotechnology company pioneering a new class of therapeutics to mediate amino acid biology, announced today the appointment of Jennifer Che, J.D., as Vice President, Intellectual Property Counsel. Ms. Che will oversee all intellectual property activities related to the protection of Pronutria’s technology and lead candidates.
“We are very pleased to welcome Jennifer to our dynamic leadership team,” said Robert Connelly, President and CEO of Pronutria Biosciences. “Her breadth of experience in patent law and intellectual property strategy will prove invaluable as we continue to expand our portfolio.”
Jennifer joins Pronutria from Cerulean Pharma (NASDAQ: CERU), where she provided legal guidance on a variety of intellectual property matters. Prior to her time at Cerulean, Jennifer spent more than a decade at Vertex Pharmaceuticals (NASDAQ: VRTX), where she directed intellectual property matters for the company’s UK and Canada research and development sites. She also led intellectual property strategy for a multitude of global drug discovery and development programs, notably in oncology, epilepsy and tuberculosis. Prior to obtaining her J.D., Jennifer was a medicinal chemist at Millennium: A Takeda Oncology Company. She earned her J.D. from Suffolk University Law School and her S.B. in Chemistry from Massachusetts Institute of Technology.
“I am thrilled to join the innovative team at Pronutria Biosciences,” said Jennifer. “I am excited to be part of a company working to help transform the lives of patients and families with unmet medical needs.”
ABOUT PRONUTRIA BIOSCIENCES
Pronutria Biosciences is pioneering new nutritional and therapeutic modalities: amino acid biologics. Amino acids (AA) are known as the “building blocks of life,” and are fundamental regulators of health. The entire body, ranging from microscopic cells to organs, is dependent on tightly controlled AA homeostasis. More than 2000 disorders are linked to differences in AA metabolism and transport. The dysregulation of AAs cause and/or drive the onset of a number of conditions. Using insights from a clinically validated body of evidence, Pronutria Biosciences is developing first-in-class therapeutic and nutritional solutions to these conditions with a focus on amino acid biology. This novel approach allows us to precisely target biology that was previously inaccessible, providing a unique opportunity to address a variety of serious nutritional and medical conditions, such as muscle, metabolic, neurological, and hepatic disorders. Founded by Flagship VentureLabs, privately-held Pronutria Biosciences is based in Cambridge, MA. For more information, please visit www.pronutriabio.com.